During the second quarter of 2018, Cortellis Competitive Intelligence registered 985 new deals (excluding mergers and acquisitions) with a total disclosed deal value of USD 19.5 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 964 and USD 35.6 billion in the first quarter and 1,104 and USD 13.6 billion in the second quarter of 2017. Total deal value in the second quarter did not quite reach the peak of 2014 (paced by Novartis' USD 16 billion purchase of GlaxoSmithKline's oncology portfolio) but eclipsed the previous quarter primarily due to Allogene's USD 2.8 billion license for Cellectis' chimeric antigen receptor T-cell immunotherapy program for cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1358/dot.2018.54.10.2909247 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Medication Safety: Reducing Administration Errors in Oncology Setting.
Asian Pac J Cancer Prev
January 2025
Center Incharge, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), University Medical City, Muscat, Oman.
Purpose: This project aimed to minimize medication errors and improve safe medication administration in an oncology setting in Muscat, Oman.
Methods: The study, spanning from the second quarter of 2022 to the first quarter of 2023, employed a one-group pretest-posttest quasi-experimental design, assessing key performance indicators (medication error and medication administration errors rates per 1000 patient days) on quarterly basis before and after implementing targeted interventions. Interventions focused on medication management processes and Healthcare Informatics System (HIS), Environment and equipment, and Education The project utilized the FOCUS PDCA (find, organize, clarify, understand, select, plan, do, check and act) methodology.
Real-world safety evaluation of brivaracetam: insights from the US FDA adverse event reporting system.
Expert Opin Drug Saf
January 2025
Shaoxing Yuecheng District People's Hospital, Shaoxing, China.
Background: Brivaracetam (BRV) is a novel drug for the treatment of epilepsy. This study aimed to detect and characterize adverse events (AEs) associated with BRV from the first quarter of 2016 to the second quarter of 2024 using the U.S.
View Article and Find Full Text PDFImpact of COVID-19 lockdowns and refugee influx on scabies presentations to dermatology outpatient clinics in Turkey.
J Infect Dev Ctries
December 2024
Faculty of Medicine, Sakarya University, Sakarya, Türkiye.
Introduction: The frequency of scabies and its relationship with the coronavirus disease 2019 (COVID-19) pandemic is a current scientific curiosity in Turkey and worldwide. The data presented in this article will help raise awareness of dermatologists in situations such as pandemic-induced quarantines where scabies can spread rapidly.
Methodology: This was a retrospective study to compare patients who presented with scabies and were evaluated during the COVID-19 pandemic, with those who presented before and after the pandemic, in terms of the diagnosis ratios.
Influenza Immunization in Very-Low-Birth-Weight Infants: Epidemiology and Long-Term Outcomes.
Vaccines (Basel)
January 2025
Airway Research Center North, German Center of Lung Research (DZL), 23562 Lübeck, Germany.
Background: Very-low-birth-weight infants (VLBWIs; birth weight < 1500 g) are at an increased risk of complicated influenza infection, which frequently includes pneumonia, encephalitis or even death. Data on influenza immunization and its outcome in VLBWIs are scarce. This study aimed to provide epidemiological data on influenza immunization for German VLBWIs and hypothesized that immunization would protect VLBWIs from infection-mediated neurodevelopmental impairment and preserves lung function at early school age.
View Article and Find Full Text PDFPhase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer.
Neuro Oncol
January 2025
Department of Breast Oncology, Moffitt Cancer Center.
Background: Screening of asymptomatic stage IV breast cancer with brain MRIs is currently not recommended by National Comprehensive Cancer Network (NCCN) Guidelines. The incidence of asymptomatic brain metastasis is not well documented.
Methods: The study is designed as a single arm, phase II trial, with the goal of investigating surveillance brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!